Category: 15. Heart Failure: Clinical
methods: A retrospective analysis of 73 consecutive patients implanted with HeartMate II LVAD was conducted. 23 (32%) patients presenting with New York Heart Association (NYHA) Class III symptoms, systemic congestion, and severe RHF on echocardiogram 1 month after LVAD implantation comprised the LRHF group. 50 (68%) patients had no signs of RHF (NRHF group). The Model for End-Stage Liver Disease (MELD) XI scores was calculated for all patients.
results:
The LRHF group patients were more often assigned for destination therapy (56% vs. 27%, p=0.01), had higher pre-operative MELD XI score (16.2 ± 4.4 vs. 13.8 ±3.2, p=0.03), lower serum albumin level (3.1 ± 0.7 vs. 3.4 ± 0.5 g/dl), tendency to higher central venous pressure (CVP, 15 ± 5 vs. 13 ± 6 mm Hg, p=0.06) and higher ratio of right ventricle to left ventricle diastolic dimension (RVDD/LVDD: 0.7 ± 0.2 vs. 0.6 ± 0.1, p=0.07) on pre-operative echocardiogram compared to the NRHF group. Preoperative MELD XI score ≥ 17 was identified in 54% of the LRHF group patients and 10% of the NRHF group patients (p = 0.001) and was the only independent predictor of LRHF (odds ratio 6.8, confidence interval 1.6 -23.1, p = 0.009) by multivariate analysis. At 6 months the LRHF patients had higher serum creatinine (1.4 ± 1.1 mg/dl vs. 1.1 ± 0.2, p=0.03), higher CVP (14.5 ± 5.7 vs. 6.3 ± 2.9 mm Hg) and RVDD/LVDD (0.8 ± 0.2 vs. 0.7 ± 0.2, p= 0.05) compared to NRHF group. In addition, 7 (29%) patients of the LRHF group versus 5 (10%) patients of the NRHF group died over 9.5 ± 6.3 months follow up period (p=0.04).
conclusions: LRHF may be predicted by pre-operative MELD XI score ≥ 17. LRHF persisted up to 6 months after LVAD implantation, and was associated with a higher mortality.
